Dr. Agarwal's Health Care Limited (AGARWALEYE) — Board Meeting | 4 August 2026

{ <|channel|>final<|message|>Here is the structured output based on the provided document: ```json "summary": "The board approved unaudited Q1 FY27 results showing revenue of ₹614 crores (+26% YoY), PAT of ₹55 crores (+44.6% YoY), and EBITDA of ₹177 crores (+25.2% YoY). It appointed S.R. Batliboi & Associates LLP as statutory auditors until the 20th AGM, KPMG as internal auditors for FY27, and re-appointed B Y & Associates as cost auditors. Plans for a wholly owned Nigerian subsidiary in ophthalmology were also detailed.", "extractedFields": { "keyEvent": "Board approves Q1 FY27 results, auditor appointments, and Nigerian subsidiary plans", "whatChanged": "Revenue grew 26% YoY to ₹614 crores; PAT surged 44.6% to ₹55 crores; new Nigerian subsidiary proposed for ophthalmology expansion", "forwardGuidance": "None", "investorTakeaway": "Strong quarterly growth and strategic expansion signal operational momentum and future revenue diversification potential.", "followUpQuestions": [ "How will the Nigerian subsidiary impact profitability?", "What is the valuation of the new ophthalmology expansion?", "How does PAT growth compare to peers?" ] }, "sentiment": "positive" }